article thumbnail

Positive results for mRNA vaccine in melanoma patients

European Pharmaceutical Review

When administered in the body, the RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity. Keytruda is an immunotherapy that works by increasing the ability of the body’s immune system to help detect and fight tumour cells.

Vaccines 115
article thumbnail

Merck to develop mAb through $10.8b acquisition

European Pharmaceutical Review

I look forward to working with the Prometheus team to establish a new paradigm of precision treatment for immune diseases,” commented Dr Dean Y Li, President of Merck Research Laboratories. Prometheus is a clinical-stage biotechnology company. “I

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Merck and Moderna partner to develop and sell cancer vaccine

Pharmaceutical Technology

The mRNA-4157/V940 has been designed to stimulate an immune response by producing T-cell responses depending on the mutational signature of a patient's tumour.

Vaccines 115
article thumbnail

Japan grants approvals for Merck’s Keytruda to treat different cancers

Pharmaceutical Technology

An anti-programmed death receptor-1 (PD-1) therapy, Keytruda acts by boosting the immune system’s ability to find and fight tumour cells. With the latest development, the antibody is indicated for 23 usages in 13 different cancer types of cancer in the country.

article thumbnail

Keytruda approved as first-line advanced cervical cancer therapy

pharmaphorum

Some cancer cells contain large amounts of PD-L1, which helps them to evade the body’s immune system. Dr Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, said the data showing a 36% reduction in the risk of death “are compelling”.

article thumbnail

Merck acquires Prometheus Biosciences

Express Pharma

Prometheus is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialisation of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. The acquisition is subject to Prometheus Biosciences shareholder approval.

article thumbnail

European Pharmaceutical Review Issue 3 2024

European Pharmaceutical Review

Taly Dvorkis Fieldfisher QA/QC MICROBIOLOGY IN DEPTH FOCUS Implementing single temperature incubation Guillaume Pinon Laboratoires SERVIER Industrie Endotoxin standards: reflection and recommendation Dr Radhakrishna Tirumalai Merck Research Laboratories (MRL) Karen Zink McCullough MMI Associates, LLC Improving aseptic connections throughout the manufacturing (..)